Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MET | P08581 | 6/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23297366 | 0.90 | HDAC1 (0.45) | TP53GLATSHRKDM4EMEN1 | |
| SCHEMBL29776802 | 0.90 | HDAC1 (0.45) | TP53GLATSHRKDM4EMEN1 | |
| SCHEMBL26160815 | 0.89 | MET (0.51) | TP53METGLAKDM4EMEN1 | |
| SCHEMBL24035613 | 0.86 | TP53 (0.50) | TP53LMNAMETGLATSHR | |
| SCHEMBL24036526 | 0.82 | HRH3 (0.44) | METTSHRKDM4EMEN1KMT2A | |
| SCHEMBL29436197 | 0.81 | MAPT (0.65) | TP53GLAKDM4EMAPT | |
| SCHEMBL23495354 | 0.81 | MAPT (0.65) | TP53GLAKDM4EMAPT | |
| SCHEMBL29776814 | 0.81 | MEN1 (0.44) | TP53METMEN1KMT2APOLB | |
| SCHEMBL23297217 | 0.81 | MEN1 (0.44) | TP53METMEN1KMT2APOLB | |
| SCHEMBL26999003 | 0.80 | PDE4B (0.54) | TP53METMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4149621-B1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS INC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-4149621-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2023-03-22 | — | — | EP | disclosed |
| WO-2021231572-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | EDGEWISE THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150977-A1 | PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES | IL6, IL1B, IL1RN | TP53 4835/4885LMNA 397/4885MET 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.